Clinical Trial Update: A Study of Adjuvant NDV-01 (Sustained-release Gemcitabine-docetaxel) for the Treatment of Intermediate Risk NMIBC Following TURBT [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating NDV-01 (sustained-release gemcitabine-docetaxel) for intermediate-risk non-muscle invasive bladder cancer following TURBT has been wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• NDV-01 (gemcitabine-docetaxel sustained-release) (gemcitabine/docetaxel sustained-release)

Snippet

Sponsor: Relmada Therapeutics, Inc. | Conditions: Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Bladder (Urothelial, Transitional Cell) Cancer | Phase 3 | Status: WITHDRAWN